YD Bio, Варрант (KYG9835J1031, YDESW)

YD Bio Ltd is a biotechnology company focused on advancing clinical trials, new drug development, cancer prevention diagnostics, and innovative therapies, especially in oncology and ophthalmology. The company emphasizes DNA methylation-based cancer detection, including tests for pancreatic cancer screening and breast cancer recurrence monitoring. It also develops stem cell- and exosome-based therapies for eye diseases through partnerships, such as with 3D Global Biotech. Additionally, YD Bio provides support services for clinical trials and has recently become publicly traded on Nasdaq via a business combination with Breeze Holdings Acquisition Corp, securing over $11.5 million in funding to accelerate innovation and growth.

• YD Bio, акция обыкновенная, KYG983011076

• Выручка
• Чистая прибыль
• EBITDA
• Активы
• Капитал
• Рентабельность по EBITDA (%)
• Чистый долг / EBITDA
• Общий долг / Капитал